Braftovi and Memory loss - a phase IV clinical study of FDA data

Summary:

Memory loss is reported as a side effect among people who take Braftovi (encorafenib), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Mektovi, and have Malignant melanoma.

The phase IV clinical study analyzes which people have Memory loss when taking Braftovi. It is created by eHealthMe based on reports of 7,606 people who have side effects when taking Braftovi from the FDA, and is updated regularly.

What is Braftovi?

Braftovi has active ingredients of encorafenib. eHealthMe is studying from 7,609 Braftovi users. Check the latest studies of Braftovi.

What is Memory loss?

Memory loss is found to be associated with 2,726 drugs and 4,378 conditions by eHealthMe. Check the latest studies of Memory loss.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 29, 2026

7,606 people reported to have side effects when taking Braftovi.
Among them, 95 people (1.25%) have Memory loss.

Among these 95 people:

How long have people been on Braftovi when they have Memory loss? *

What is the gender of people who have Memory loss when taking Braftovi? *

female: 67.44 %
male: 32.56 %

What is the age of people who have Memory loss when taking Braftovi? *

What are other drugs people take besides Braftovi? *

What are other side effects people have besides Memory loss? *

Fatigue (feeling of tiredness): 32 people, 33.68%
Neoplasm Progression (growth of tumour): 21 people, 22.11%
Diarrhea: 15 people, 15.79%
Nausea (feeling of having an urge to vomit): 11 people, 11.58%
Abdominal Pain Upper: 11 people, 11.58%
Confusional State: 11 people, 11.58%
Second Primary Malignancy (after getting cure a cancer, a new cancer development): 10 people, 10.53%
Rashes (redness): 9 people, 9.47%
Weakness: 8 people, 8.42%
Constipation: 7 people, 7.37%

What are the existing conditions these people have? *

Malignant Melanoma (skin cancer rises from melancytes): 26 people, 27.37%
Colon Cancer: 10 people, 10.53%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 7 people, 7.37%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 7 people, 7.37%
Brain Neoplasm Malignant (brain cancer tumour): 6 people, 6.32%
Neoplasm Malignant (cancer tumour): 3 people, 3.16%
Thrombosis (formation of a blood clot inside a blood vessel): 2 people, 2.11%
Skin Injury: 2 people, 2.11%
Hypersensitivity: 2 people, 2.11%
Astrocytoma Malignant (cancerous tumour of brain that originate in a particular kind of glial-cells): 2 people, 2.11%

* Approximation only. Some reports may have incomplete information.

Do you take Braftovi and have Memory loss?

- Check whether Memory loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Braftovi:

Braftovi (7,609 reports)

Memory loss treatments and more:

Memory loss (244,445 reports)

Browse all side effects of Braftovi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Memory loss:

Memory loss (2,726 drugs)

Browse all the conditions that are associated with Memory loss:

Memory loss (4,378 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on encorafenib (the active ingredients of Braftovi) and Braftovi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.